Development and validation of a method for human papillomavirus genotyping based on molecular beacon probes.

We describe a new assaying system for the detection and genotyping of human papillomavirus (HPV) based on linear-after-the-exponential-PCR(LATE-PCR) and melting curve analysis. The 23 most prevalent HPV strains (types 6, 11, 16, 18, 31, 33, 35, 39, 42, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, 81,...

Full description

Bibliographic Details
Main Authors: Jiangfeng Lyu, Yuefeng Yu, Caixia Pan, Jing Zhou, Xuyi Ren
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0207930
id doaj-9a5705bfff484f949126243c7f150093
record_format Article
spelling doaj-9a5705bfff484f949126243c7f1500932021-03-03T21:04:55ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-011311e020793010.1371/journal.pone.0207930Development and validation of a method for human papillomavirus genotyping based on molecular beacon probes.Jiangfeng LyuYuefeng YuCaixia PanJing ZhouXuyi RenWe describe a new assaying system for the detection and genotyping of human papillomavirus (HPV) based on linear-after-the-exponential-PCR(LATE-PCR) and melting curve analysis. The 23 most prevalent HPV strains (types 6, 11, 16, 18, 31, 33, 35, 39, 42, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, 81, 82, and 83) are assayed in two sealed reaction tubes within 2 h. Good sensitivity and specificity was evaluated by testing cloned HPV DNA and clinical samples. The detection limit was 5-500 copies/reaction depending on the genotype. No cross-reactivity was observed with the other HPV types that are not covered by our method or pathogens tested which were commonly found in female genital tract. When compared with the HPV GenoArray Diagnostic kit, the results from 1104 clinical samples suggest good overall agreement between the two methods,(98.37%, 95% CI: 97.44%-98.97%) and the kappa value was 0.954. Overall, this new HPV genotyping assay system presents a simple, rapid, universally applicable, sensitive, and highly specific detection methodology that should be useful for HPV detection and genotyping, therefore, is potentially of great value in clinical application.https://doi.org/10.1371/journal.pone.0207930
collection DOAJ
language English
format Article
sources DOAJ
author Jiangfeng Lyu
Yuefeng Yu
Caixia Pan
Jing Zhou
Xuyi Ren
spellingShingle Jiangfeng Lyu
Yuefeng Yu
Caixia Pan
Jing Zhou
Xuyi Ren
Development and validation of a method for human papillomavirus genotyping based on molecular beacon probes.
PLoS ONE
author_facet Jiangfeng Lyu
Yuefeng Yu
Caixia Pan
Jing Zhou
Xuyi Ren
author_sort Jiangfeng Lyu
title Development and validation of a method for human papillomavirus genotyping based on molecular beacon probes.
title_short Development and validation of a method for human papillomavirus genotyping based on molecular beacon probes.
title_full Development and validation of a method for human papillomavirus genotyping based on molecular beacon probes.
title_fullStr Development and validation of a method for human papillomavirus genotyping based on molecular beacon probes.
title_full_unstemmed Development and validation of a method for human papillomavirus genotyping based on molecular beacon probes.
title_sort development and validation of a method for human papillomavirus genotyping based on molecular beacon probes.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2018-01-01
description We describe a new assaying system for the detection and genotyping of human papillomavirus (HPV) based on linear-after-the-exponential-PCR(LATE-PCR) and melting curve analysis. The 23 most prevalent HPV strains (types 6, 11, 16, 18, 31, 33, 35, 39, 42, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, 81, 82, and 83) are assayed in two sealed reaction tubes within 2 h. Good sensitivity and specificity was evaluated by testing cloned HPV DNA and clinical samples. The detection limit was 5-500 copies/reaction depending on the genotype. No cross-reactivity was observed with the other HPV types that are not covered by our method or pathogens tested which were commonly found in female genital tract. When compared with the HPV GenoArray Diagnostic kit, the results from 1104 clinical samples suggest good overall agreement between the two methods,(98.37%, 95% CI: 97.44%-98.97%) and the kappa value was 0.954. Overall, this new HPV genotyping assay system presents a simple, rapid, universally applicable, sensitive, and highly specific detection methodology that should be useful for HPV detection and genotyping, therefore, is potentially of great value in clinical application.
url https://doi.org/10.1371/journal.pone.0207930
work_keys_str_mv AT jiangfenglyu developmentandvalidationofamethodforhumanpapillomavirusgenotypingbasedonmolecularbeaconprobes
AT yuefengyu developmentandvalidationofamethodforhumanpapillomavirusgenotypingbasedonmolecularbeaconprobes
AT caixiapan developmentandvalidationofamethodforhumanpapillomavirusgenotypingbasedonmolecularbeaconprobes
AT jingzhou developmentandvalidationofamethodforhumanpapillomavirusgenotypingbasedonmolecularbeaconprobes
AT xuyiren developmentandvalidationofamethodforhumanpapillomavirusgenotypingbasedonmolecularbeaconprobes
_version_ 1714818936411783168